The US Food and Drug Administration (FDA) has re-authorised the emergency use authorization (EUA) for Meridian Bioscience’s Revogene SARS-CoV-2 molecular assay.

The regulator initially granted EUA for the Covid-19 molecular diagnostic test last November.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

However, the company decided to delay the marketing of the assay so that its design could be modified to correctly detect the Omicron variant.

Meridian Bioscience completed this development work and submitted an initial set of data to the FDA for validation of the redesigned assay’s performance in March.

Later, the company completed additional clinical studies to obtain EUA re-authorisation.

It intends to commence shipping of the assay before the end of its fiscal fourth quarter, which ends on 30 September.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A real-time RT-PCR test, Revogene SARS-CoV-2 has been designed to detect RNA from SARS-CoV-2 in anterior nasal, nasopharyngeal, oropharyngeal and mid-turbinate nasal swab samples collected from individuals who are suspected of having Covid-19 by their healthcare provider.

It runs on the company’s Revogene platform and can provide positive results in 47 minutes.

The company stated that the test has demonstrated good clinical performance, with 97.7% of negative and positive predictive agreements.

Meridian Bioscience Diagnostics executive vice-president Tony Serafini-Lamanna said: “There continues to be demand for fast, accurate detection of Covid-19, especially considering the high transmissibility of these new variants and the upcoming respiratory season.

“We believe our Revogene SARS-CoV-2 assay and growing Revogene platform can help clinicians and health systems meet these demands now and in the future.”

The company’s fully automated Revogene molecular platform can easily integrate into any laboratory or health system and optimise the laboratory’s Covid-19 testing capacity in two steps.

Other FDA-approved tests that can run on the Revogene platform include Revogene Carba C, Revogene Strep A, Revogene C difficile and Revogene GBS LB.